NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a report issued on Tuesday morning,Benzinga reports. They currently have a $14.00 target price on the stock.

A number of other brokerages have also recently commented on NRSN. Roth Mkm assumed coverage on shares of NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 price target for the company. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Performance

Shares of NRSN stock opened at $0.82 on Tuesday. The firm has a fifty day moving average of $0.93 and a 200-day moving average of $1.02. NeuroSense Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.60.

Hedge Funds Weigh In On NeuroSense Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the third quarter worth approximately $26,000. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the 4th quarter worth approximately $77,000. Finally, Squarepoint Ops LLC increased its holdings in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.